<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">AES</journal-id>
<journal-id journal-id-type="hwp">spaes</journal-id>
<journal-id journal-id-type="nlm-ta">Aesthet Surg J</journal-id>
<journal-title>Aesthetic Surgery Journal</journal-title>
<issn pub-type="ppub">1090-820X</issn>
<issn pub-type="epub">1527-330X</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1090820X12455659</article-id>
<article-id pub-id-type="publisher-id">10.1177_1090820X12455659</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Oculoplastic Surgery</subject>
<subj-group subj-group-type="heading">
<subject>Case Report</subject>
</subj-group>
</subj-group>
<subj-group subj-group-type="hwp-journal-coll">
<subject>20</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Topical Bimatoprost 0.03% and Iatrogenic Eyelid and Orbital Lipodystrophy</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Sira</surname><given-names>Mano</given-names></name>
<degrees>BSC, FRCOphth</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Verity</surname><given-names>David Harding</given-names></name>
<degrees>MA, MD, FRCOphth</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Malhotra</surname><given-names>Raman</given-names></name>
<degrees>FRCOphth</degrees>
</contrib>
</contrib-group>
<aff id="aff1-1090820X12455659">Dr Sira is a Fellow and Dr Malhotra is a Consultant Surgeon in Orbital, Oculoplastic, and Lacrimal Surgery in the Corneoplastic Unit, Queen Victoria Hospital NHS Foundation Trust, East Grinstead, West Sussex, UK</aff>
<aff id="aff2-1090820X12455659">Dr Verity is a Consultant Oculoplastic Surgeon in Orbital Service at Moorfields Eye Hospital, London, UK</aff>
<author-notes>
<corresp id="corresp1-1090820X12455659">Dr Mano Sira, Corneoplastic Unit, Queen Victoria Hospital NHS Foundation Trust, East Grinstead, West Sussex, UK, RH19 3DZ E-mail: <email>manosira@doctors.net.uk</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>9</month>
<year>2012</year>
</pub-date>
<volume>32</volume>
<issue>7</issue>
<fpage>822</fpage>
<lpage>824</lpage>
<history>
<date date-type="accepted">
<day>21</day>
<month>5</month>
<year>2012</year>
</date>
</history>
<permissions>
<copyright-statement>© 2012 The American Society for Aesthetic Plastic Surgery, Inc.</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="society">American Society for Aesthetic Plastic Surgery, Inc.</copyright-holder>
</permissions>
<abstract>
<p>The prostaglandin F2a (PGF2a) analogue bimatoprost 0.03% (Allergan, Inc, Irvine, California) has been employed for the treatment of hypotrichosis since it gained Food and Drug Administration approval as Latisse in 2008. In this report, the authors retrospectively review the cases of 7 patients who presented to their outpatient ophthalmology clinic with glaucoma. These patients had periorbital hollowing due to fat atrophy as a side effect of topical ophthalmic bimatoprost therapy. The series of patients described in this report emphasizes the small but significant risk of periocular fat changes associated with bimatoprost 0.03%, which is the exact formulation marketed as Lumigan for glaucoma treatment. Patients using Latisse for its cosmetic enhancement of eyelash length should be warned of this potentially disfiguring side effect, since the cosmetic and ophthalmic preparations are identical. Such changes can be irreversible, and the implications of the decision to prescribe this drug either in the form of an eyelash application or for topical ophthalmic use should be clearly understood by both clinicians and patients alike.</p>
<p><bold>Level of Evidence:</bold> 4</p>
<p><inline-graphic xlink:href="10.1177_1090820X12455659-img1.tif"/></p>
</abstract>
<kwd-group>
<kwd>oculoplastics orbital</kwd>
<kwd>periorbital</kwd>
<kwd>lipodystrophy</kwd>
<kwd>fat atrophy</kwd>
<kwd>Latisse</kwd>
<kwd>bimatoprost</kwd>
<kwd>Lumigan</kwd>
<kwd>periorbital hollows</kwd>
<kwd>eyelid sulci</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>The prostaglandin F2a (PGF2a) analogue bimatoprost 0.03% (Allergan, Inc, Irvine, California) has been employed for the treatment of hypotrichosis since it gained Food and Drug Administration (FDA) approval as Latisse in 2008, about 7 years after its license was granted for use in an identical formulation, to treat glaucoma in 2001 (Lumigan; Allergan, Inc).</p>
<p>Periorbital lipodystrophy, including upper eyelid sulcus deepening and upper eyelid retraction following use of bimatoprost 0.03%, travoprost 0.004% (Lumigan; Allergan Inc, Irvine, California), and most recently latanaprost 0.005% (Xalatan; Pfizer, Pharmacia &amp; Upjohn Company, New York, New York), has been previously reported.<sup><xref ref-type="bibr" rid="bibr1-1090820X12455659">1</xref>
<xref ref-type="bibr" rid="bibr2-1090820X12455659"/><xref ref-type="bibr" rid="bibr3-1090820X12455659"/><xref ref-type="bibr" rid="bibr4-1090820X12455659"/><xref ref-type="bibr" rid="bibr5-1090820X12455659"/><xref ref-type="bibr" rid="bibr6-1090820X12455659"/><xref ref-type="bibr" rid="bibr7-1090820X12455659"/>-<xref ref-type="bibr" rid="bibr8-1090820X12455659">8</xref></sup> However, with the advent of Latisse in medical aesthetic practice, it is important to consider the small but significant risks of these potentially disfiguring side effects, since the cosmetic and ophthalmic preparations are identical. This potential side effect of Latisse has not been previously reported in the literature.</p>
<p>We present 7 cases of periorbital hollowing due to fat atrophy as a side effect of topical ophthalmic bimatoprost therapy. These effects improved in patients who discontinued therapy, and in 1 case, the effects improved while the patient remained on long-term therapy.</p>
<sec id="section1-1090820X12455659">
<title>Case Presentations</title>
<p>Between 2004 and 2011, 7 patients (3 men, 4 women) with an average age of 73 years (range, 56-84 years) presented to the authors with periorbital hollowing due to fat atrophy as a side effect of topical ophthalmic bimatoprost therapy (<xref ref-type="table" rid="table1-1090820X12455659">Table 1</xref> and <xref ref-type="fig" rid="fig1-1090820X12455659">Figures 1</xref><xref ref-type="fig" rid="fig2-1090820X12455659"/>-<xref ref-type="fig" rid="fig3-1090820X12455659">3</xref>). Their cases were retrospectively reviewed. A series of this kind has obvious limitations due to its retrospective nature, but side effects including conjunctival hyperemia, iris pigmentation, lid pigmentation, hair growth outside the treatment area, intraocular inflammation, and macular edema are well reported.<sup><xref ref-type="bibr" rid="bibr9-1090820X12455659">9</xref></sup></p>
<table-wrap id="table1-1090820X12455659" position="float">
<label>Table 1.</label>
<caption><p>Table of Clinical Features</p></caption>
<graphic alternate-form-of="table1-1090820X12455659" xlink:href="10.1177_1090820X12455659-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup>
<thead>
<tr>
<th align="left">Clinical Feature</th>
<th align="center">Patient 1</th>
<th align="center">Patient 2</th>
<th align="center">Patient 3</th>
<th align="center">Patient 4</th>
<th align="center">Patient 5</th>
<th align="center">Patient 6</th>
<th align="center">Patient 7</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (y), sex (pretreatment photo)</td>
<td>56, male</td>
<td>75, male (<xref ref-type="fig" rid="fig1-1090820X12455659">Figure 1a</xref>)</td>
<td>65, female</td>
<td>84, female</td>
<td>78, male</td>
<td>75, female</td>
<td>75, female</td>
</tr>
<tr>
<td>Treatment</td>
<td>Bimatoprost 0.03%, timolol 0.5%</td>
<td>Bimatoprost 0.03%</td>
<td>Bimatoprost 0.03%</td>
<td>Bimatoprost 0.03%</td>
<td>Bimatoprost 0.03%</td>
<td>Bimatoprost 0.03%</td>
<td>Bimatoprost 0.03%</td>
</tr>
<tr>
<td>Diagnosis and laterality</td>
<td>Secondary glaucoma, right eye</td>
<td>POAG, both eyes</td>
<td>POAG, both eyes</td>
<td>POAG, therapy to left eye only</td>
<td>POAG, left eye</td>
<td>POAG, both eyes</td>
<td>Normal tension glaucoma, left eye</td>
</tr>
<tr>
<td>Duration of therapy, mo</td>
<td>60</td>
<td>8</td>
<td>84</td>
<td>48</td>
<td>60</td>
<td>60</td>
<td>36</td>
</tr>
<tr>
<td>Effect</td>
<td>H, L, S, P</td>
<td>H, L, S, P (<xref ref-type="fig" rid="fig1-1090820X12455659">Figure 1b</xref>)</td>
<td>H, L, S, C</td>
<td>H, L, S (<xref ref-type="fig" rid="fig2-1090820X12455659">Figure 2a</xref>)</td>
<td>H, L, S, P (<xref ref-type="fig" rid="fig3-1090820X12455659">Figure 3a</xref>)</td>
<td>H, S</td>
<td>H</td>
</tr>
<tr>
<td>Change in treatment</td>
<td>None</td>
<td>Switched to latanaprost 0.005%</td>
<td>Switched to latanaprost 0.005%</td>
<td>None</td>
<td>None</td>
<td>Switched to latanaprost 0.005%</td>
<td>Switched to latanaprost 0.005%</td>
</tr>
<tr>
<td>Outcome</td>
<td>Improvement while on continued bimatoprost therapy</td>
<td>Not documented</td>
<td>Not documented</td>
<td>No improvement</td>
<td>Not documented</td>
<td>Improvement after changing to latanaprost</td>
<td>Improvement after changing to latanaprost</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1090820X12455659">
<p>Abbreviations: C, conjunctival hyperemia; H, eyelid hollows; L, increased lash length; P, increased palpebral aperture; POAG, primary open-angle glaucoma; S, skin hyperpigmentation.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<fig id="fig1-1090820X12455659" position="float">
<label>Figure 1.</label>
<caption><p>(A) This 75-year-old man is shown prior to commencing bimatoprost therapy. (B) After 8 months of treatment with bimatoprost to both eyes. Note the deepening of upper and lower eyelid sulci.</p></caption>
<graphic xlink:href="10.1177_1090820X12455659-fig1.tif"/>
</fig>
<fig id="fig2-1090820X12455659" position="float">
<label>Figure 2.</label>
<caption><p>This 84-year-old woman is shown after 48 months of treatment with bimatoprost to the left eye. Note upper and lower eyelid hollowing.</p></caption>
<graphic xlink:href="10.1177_1090820X12455659-fig2.tif"/>
</fig>
<fig id="fig3-1090820X12455659" position="float">
<label>Figure 3.</label>
<caption><p>This 78-year-old man, who reported only a history of “firmness around the orbit” with no other ocular or orbital symptoms, is shown after 60 months of treatment with bimatoprost to the left eye. Note upper and lower eyelid hollowing.</p></caption>
<graphic xlink:href="10.1177_1090820X12455659-fig3.tif"/>
</fig>
<p>It is a point of note that glaucoma is well described in unilateral cases due to pseudoexfoliation or asymmetrical glaucoma, for example. The decision to treat unilaterally is based on optic disc and visual field changes, as well as intraocular pressure. Orbital imaging studies (computed tomography scan) were carried out in several patients from our series. There was no evidence of any cicatrising process, nor was there any sign or symptom of diplopia in any of the patients.</p>
<p>Upper and lower eyelid hollowing due to preaponeurotic and orbital lipodystrophy and possible activation of Muller’s muscle<sup><xref ref-type="bibr" rid="bibr8-1090820X12455659">8</xref></sup> can cause retraction of the upper lid and inferior displacement of the lower lid, thus widening the palpebral aperture. Typically, an improvement in these signs is noted on cessation of therapy,<sup><xref ref-type="bibr" rid="bibr1-1090820X12455659">1</xref>,<xref ref-type="bibr" rid="bibr2-1090820X12455659">2</xref>,<xref ref-type="bibr" rid="bibr4-1090820X12455659">4</xref><xref ref-type="bibr" rid="bibr5-1090820X12455659"/>-<xref ref-type="bibr" rid="bibr6-1090820X12455659">6</xref>,<xref ref-type="bibr" rid="bibr8-1090820X12455659">8</xref></sup> although, in this series, periorbital hollowing improved in 1 patient while still on bimatoprost. Interestingly, bimatoprost has recently become available in a lower concentration of 0.01%; this is equally efficacious in lowering intraocular pressure,<sup><xref ref-type="bibr" rid="bibr10-1090820X12455659">10</xref></sup> but whether the effect on eyelash growth is the same, or lower than the higher concentration, remains unknown.</p>
<p>In bimatoprost-related acquired lipodystrophy, local adipocyte atrophy is thought to be due to upregulation of prostaglandin F2-α, a molecule known to have potent antiadipogenic effects. Latisse, intended to enhance lash growth but being identical to Lumigan in formulation, carries the same risks of periocular changes. Since the dermatological side effects of bimatoprost can be attenuated by reducing the drop-skin contact,<sup><xref ref-type="bibr" rid="bibr11-1090820X12455659">11</xref></sup> it is reasonable to presume that the risk of periocular lipodystrophy can likewise be reduced if the application of Latisse is limited to the lash bases along the eyelid margin.</p>
<p>If the product is applied to the cutaneous lid margin as instructed and spillover onto the ocular surface does not occur, then clinicians can be reassured that there is no current evidence base to suggest this complication would occur. The lid margin has both a cutaneous and a mucosal surface. No evidence exists to suggest that solely cutaneous application would result in intraocular delivery or lipoatrophy. It should be pointed out that cutaneous application of steroid creams, for example, can result in intraocular delivery, causing cataracts and glaucoma, but this has not been shown with bimatoprost. Conversely, ocular surface-only use of bimatoprost can result in cutaneous changes such as hyperpigmentation.</p>
</sec>
<sec id="section2-1090820X12455659">
<title>Conclusions</title>
<p>The series of patients described in this report emphasizes the small but significant risk of periocular fat changes associated with bimatoprost 0.03%. Patients using Latisse for its cosmetic enhancement of eyelash length should be warned of this potentially disfiguring side effect, since the cosmetic and ophthalmic preparations are identical, and with even 1 drop a day contacting the ocular surface, this is effectively the same regime. Such changes can be irreversible, and the decision to prescribe this drug either in the form of an eyelash application or for topical ophthalmic use should be clearly understood by both clinician and patient alike.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="conflict">
<label>Disclosures</label>
<p>The authors declared no potential conflicts of interest with respect to the research, authorship, and publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>The authors received no financial support for the research, authorship, and publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1090820X12455659">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Peplinski</surname><given-names>LS</given-names></name>
<name><surname>Albiani Smith</surname><given-names>K</given-names></name>
</person-group>. <article-title>Deepening of lid sulcus from topical bimatoprost therapy</article-title>. <source>Optom Vis Sci</source>. <year>2004</year>;<volume>81</volume>:<fpage>574</fpage>-<lpage>577</lpage>.</citation>
</ref>
<ref id="bibr2-1090820X12455659">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Filippopoulos</surname><given-names>T</given-names></name>
<name><surname>Paula</surname><given-names>JS</given-names></name>
<name><surname>Torun</surname><given-names>N</given-names></name>
<name><surname>Hatton</surname><given-names>MP</given-names></name>
<name><surname>Pasquale</surname><given-names>LR</given-names></name>
<name><surname>Grosskreutz</surname><given-names>CL</given-names></name>
</person-group>. <article-title>Periorbital changes associated with topical bimatoprost</article-title>. <source>Ophthal Plast Reconstr Surg</source>. <year>2008</year>;<volume>24</volume>:<fpage>302</fpage>-<lpage>307</lpage>.</citation>
</ref>
<ref id="bibr3-1090820X12455659">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tappeiner</surname><given-names>C</given-names></name>
<name><surname>Perren</surname><given-names>B</given-names></name>
<name><surname>Iliev</surname><given-names>ME</given-names></name>
<name><surname>Frueh</surname><given-names>BE</given-names></name>
<name><surname>Goldblum</surname><given-names>D</given-names></name>
</person-group>. <article-title>Orbital fat atrophy in glaucoma patients treated with topical bimatoprost—can bimatoprost cause enophthalmos?</article-title> <source>Klin Monbl Augenheilkd</source>. <year>2008</year>;<volume>225</volume>:<fpage>443</fpage>-<lpage>445.</lpage></citation>
</ref>
<ref id="bibr4-1090820X12455659">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yam</surname><given-names>JC</given-names></name>
<name><surname>Yuen</surname><given-names>NS</given-names></name>
<name><surname>Chan</surname><given-names>CW</given-names></name>
</person-group>. <article-title>Bilateral deepening of upper lid sulcus from topical bimatoprost therapy</article-title>. <source>J Ocul Pharmacol Ther</source>. <year>2009</year>;<volume>25</volume>:<fpage>471</fpage>-<lpage>472</lpage>.</citation>
</ref>
<ref id="bibr5-1090820X12455659">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jayaprakasam</surname><given-names>A</given-names></name>
<name><surname>Ghazi-Nouri</surname><given-names>S</given-names></name>
</person-group>. <article-title>Periorbital fat atrophy—an unfamiliar side effect of prostaglandin analogues</article-title>. <source>Orbit</source>. <year>2010</year>;<volume>29</volume>:<fpage>357</fpage>-<lpage>359.</lpage></citation>
</ref>
<ref id="bibr6-1090820X12455659">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yang</surname><given-names>HK</given-names></name>
<name><surname>Park</surname><given-names>KH</given-names></name>
<name><surname>Kim</surname><given-names>TW</given-names></name>
<name><surname>Kim</surname><given-names>DM</given-names></name>
</person-group>. <article-title>Deepening of eyelid superior sulcus during topical travoprost treatment</article-title>. <source>Jpn J Ophthalmol</source>. <year>2009</year>;<volume>53</volume>:<fpage>176</fpage>-<lpage>179.</lpage></citation>
</ref>
<ref id="bibr7-1090820X12455659">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ung</surname><given-names>T</given-names></name>
<name><surname>Currie</surname><given-names>ZI</given-names></name>
</person-group>. <article-title>Periocular changes following long-term administration of latanoprost 0.005%</article-title>. <source>Ophthal Plast Reconstr Surg</source>. <year>2012</year>;<volume>28</volume>(<issue>2</issue>):<fpage>e42</fpage>-<lpage>e44.</lpage></citation>
</ref>
<ref id="bibr8-1090820X12455659">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Noma</surname><given-names>K</given-names></name>
<name><surname>Kakizaki</surname><given-names>H</given-names></name>
</person-group>. <article-title>Bilateral upper eyelid retraction caused by topical bimatoprost therapy</article-title>. <source>Ophthal Plast Reconstr Surg</source>. <year>2012</year>;<volume>28</volume>(<issue>2</issue>):<fpage>e33</fpage>-<lpage>e35</lpage>.</citation>
</ref>
<ref id="bibr9-1090820X12455659">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Holló</surname><given-names>G</given-names></name>
</person-group>. <article-title>The side effects of the prostaglandin analogues</article-title>. <source>Expert Opin Drug Saf</source>. <year>2007</year>;<volume>6</volume>:<fpage>45</fpage>-<lpage>52.</lpage></citation>
</ref>
<ref id="bibr10-1090820X12455659">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Katz</surname><given-names>LJ</given-names></name>
<name><surname>Cohen</surname><given-names>JS</given-names></name>
<name><surname>Batoosingh</surname><given-names>AL</given-names></name>
<name><surname>Felix</surname><given-names>C</given-names></name>
<name><surname>Shu</surname><given-names>V</given-names></name>
<name><surname>Schiffman</surname><given-names>RM</given-names></name>
</person-group>. <article-title>Twelve-month, randomized, controlled trial of bimatoprost 0.01%, 0.0125%, and 0.03% in patients with glaucoma or ocular hypertension</article-title>. <source>Am J Ophthalmol</source>. <year>2010</year>;<volume>149</volume>:<fpage>661</fpage>-<lpage>671</lpage>.</citation>
</ref>
<ref id="bibr11-1090820X12455659">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Centofanti</surname><given-names>M</given-names></name>
<name><surname>Oddone</surname><given-names>F</given-names></name>
<name><surname>Chimenti</surname><given-names>S</given-names></name>
<name><surname>Tanga</surname><given-names>L</given-names></name>
<name><surname>Citarella</surname><given-names>L</given-names></name>
<name><surname>Manni</surname><given-names>G</given-names></name>
</person-group>. <article-title>Prevention of dermatologic side effects of bimatoprost 0.03% topical therapy</article-title>. <source>Am J Ophthalmol</source>. <year>2006</year>;<volume>142</volume>:<fpage>1059</fpage>-<lpage>1060</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>